首页> Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico> Clinical outcomes of FOLFIRINOX and gemcitabine-nab paclitaxel for metastatic pancreatic cancer in the real world setting.

Clinical outcomes of FOLFIRINOX and gemcitabine-nab paclitaxel for metastatic pancreatic cancer in the real world setting.

导出 LinkOut

翻译打印收藏纠错

第一作者： F,Franco

第一单位： Department of Medical Oncology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain. f3franc@gmail.com.

作者： F,Franco ^[1] ; J C,Camara ^[2] ; J I,Martín-Valadés ^[3] ; A,López-Alfonso ^[4] ; D,Marrupe ^[5] ; D,Gutiérrez-Abad ^[6] ; B,Martínez-Amores ^[7] ; A,León ^[3] ; I,Juez ^[6] ; M,Pérez ^[4] ; A,Royuela ^[8] ; A,Ruiz-Casado ^[9]

作者单位： Department of Medical Oncology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain. f3franc@gmail.com. ^[1] Department of Medical Oncology, Fundación Hospital Alcorcón, Alcorcón, Spain. ^[2] Department of Medical Oncology, Fundación Jiménez Díaz, Madrid, Spain. ^[3] Department of Medical Oncology, Hospital Universitario Infanta Leonor, Madrid, Spain. ^[4] Department of Medical Oncology, Hospital Universitario de Móstoles, Móstoles, Spain. ^[5] Department of Medical Oncology, Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain. ^[6] Department of Medical Oncology, Hospital Universitario Rey Juan Carlos, Móstoles, Spain. ^[7] Department of Biostatistics, Hospital Universitario Puerta de Hierro, Majadahonda, Spain. ^[8] Department of Medical Oncology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain. ^[9]

关键词 Chemotherapy Metastatic pancreatic cancer Overall survival Palliative care Toxicity of treatment